| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
52,854,000 |
| Market
Cap: |
3.57(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$47.99 - $69.65 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Axonics is a medical technology company that develops and commercializes products for adults with bladder and bowel dysfunction, including: implantable sacral neuromodulation (SNM) systems to treat urinary urge incontinence and urinary urgency frequency, together referred to as overactive bladder, as well as fecal incontinence, and non-obstructive urinary retention; and a urethral bulking agent to treat female stress urinary incontinence. Co.'s proprietary rechargeable SNM system is designed to provide magnetic resonance imaging access, programmers, and long recharging interval among rechargeable SNM systems.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
106,451 |
138,394 |
601,869 |
| Total Sell Value |
$0 |
$7,194,886 |
$9,040,714 |
$40,119,230 |
| Total People Sold |
0 |
5 |
6 |
9 |
| Total Sell Transactions |
0 |
8 |
12 |
43 |
| End Date |
2024-02-18 |
2023-11-17 |
2023-05-19 |
2022-05-19 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Pardo Geoff |
|
– – • |
2019-04-12 |
4 |
D |
$0.00 |
$0 |
D/D |
(417) |
2,083 |
|
- |
|
| Kiernan Jane E |
Director |
– • – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Snyderman Nancy Lynn Md |
Director |
– • – |
2019-04-08 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Sama Rinda |
Chief Operating Officer |
• – – |
2019-03-06 |
4 |
A |
$0.00 |
$0 |
I/I |
4,000 |
4,000 |
|
- |
|
| Carrel Michael H |
Director |
– • – |
2019-02-27 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
5,000 |
|
- |
|
| Mcnamara Robert E |
Director |
– • – |
2018-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
6,500 |
|
- |
|
| Pardo Geoff |
Director |
– • • |
2018-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Tammenoms Bakker Juliet |
Director |
– • • |
2018-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Amble Erik |
Director |
– • – |
2018-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Malik Shahzad |
Director |
– • – |
2018-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Petrovich John George |
Director |
– • – |
2018-12-06 |
4 |
A |
$0.00 |
$0 |
D/D |
2,500 |
2,500 |
|
- |
|
| Petrovich John George |
Former 10% Owner |
– • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,214,970 |
2,102,970 |
|
- |
|
| Advent Life Sciences Fund Ii Lp |
Former 10% Owner |
– – – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,694,349 |
1,694,349 |
|
- |
|
| Cohen Raymond W |
Chief Executive Officer |
• • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
8,760 |
688,651 |
|
- |
|
| Jiang Guangqiang |
Chief Technology Officer |
• – – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
2,626 |
201,896 |
|
- |
|
| Biodiscovery 4 Fcpr |
10% Owner |
– – • |
2018-11-02 |
4 |
B |
$15.00 |
$12,999,990 |
I/I |
866,666 |
3,557,461 |
1.5 |
- |
|
| Biodiscovery 4 Fcpr |
10% Owner |
– – • |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,690,795 |
2,690,795 |
|
- |
|
| Malik Shahzad |
Former 10% Owner |
– • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,694,349 |
1,694,349 |
|
- |
|
| Wisniewski Raphael |
Director |
– • • |
2018-11-02 |
4 |
B |
$15.00 |
$12,999,990 |
I/I |
866,666 |
3,557,461 |
2.25 |
- |
|
| Wisniewski Raphael |
Director |
– • • |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,690,795 |
2,690,795 |
|
- |
|
| Amble Erik |
Former 10% Owner |
– • – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,520,884 |
1,520,884 |
|
- |
|
| Neomed Innovation V L.p. |
Former 10% Owner |
– – – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
1,520,884 |
1,520,884 |
|
- |
|
| Cooperatieve Gilde Healthcare Iv U.a. |
10% Owner |
– – • |
2018-11-02 |
4 |
B |
$15.00 |
$12,999,990 |
I/I |
866,666 |
3,133,332 |
1.5 |
- |
|
| Cooperatieve Gilde Healthcare Iv U.a. |
10% Owner |
– – • |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
I/I |
2,266,666 |
2,266,666 |
|
- |
|
| Alfred E. Mann Foundation For Scientific Research |
Former 10% Owner |
– – – |
2018-11-02 |
4 |
A |
$0.00 |
$0 |
D/D |
1,214,970 |
2,102,970 |
|
- |
|
334 Records found
|
|
Page 13 of 14 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.12 (0.18%) 
